A Novel Petide for the Control of Cancer

Novel peptide which when given to cancer cells inhibits their growth in a cell culture system

Oxidative stress is a persistent and often irreversible oxidative shift that has been defined as an imbalance between oxidants and antioxidants in favor of the former. This imbalance results in an increase in cellular reduction/oxidation reactions. Oxidative stress is implicated in the pathogenesis of several diseases. Diseases targeted are primlary cancer, but not closed too as other areas included are inflammatory disorders, cardiovascular and neuro de-generative disorders, sepsis, re-perfusion damage, rheumatoid arthritis, osteoarthritis, and diabetes.

Dr. Basil Rigas, Professor of Medicine and Professor of Pharmacological Sciences, has synthesized novel and patented peptides that contain at least two cysteine residues capable of forming one or more disulfide bridges. When given to cancer cells inhibits their growth in a cell culture system. Preliminary data indicate that this peptide is effective in slowing the growth of cancer and inflammation in a murine xenograft tumor model. This peptide enhanced the anticancer effect of other anticancer agents.

Patented peptide compositions to be used either alone or in conjunction with other known therapies. Peptide enhanced the anticancer effect of other anticancer agents.

Therapeutics, Peptides, Cancer, Inflammation

preclinical

Available for License

Cancer

https://stonybrook.technologypublisher.com/files/sites/therapeutics1.jpg 

Patent Information:
Technology/Start-up ID: